Effect of steroids on the activation status of platelets in patients with Immune thrombocytopenia (ITP)
Authors:
- 10 February 2014
- journal article
- Published by Taylor & Francis in Platelets
- Vol. 26 (2) , 119-126
Abstract
The activation status of platelets in Immune Thrombocytopenia (ITP) patients--which is still somewhat controversial--is of potential interest, because activated platelets tend to aggregate (leading to excessive clotting or thromboembolic events) but cannot do so when platelet numbers are low, as in ITP. Although corticosteroids are the first line of therapy in ITP, the effect of steroids on activation of platelets has not been evaluated so far. We examined the status of platelet activation (with and without stimulation with ADP) in ITP patients, at the start of therapy (pre-steroid treatment, naive) and post-steroid treatment (classified on the basis of steroid responsiveness). We used flow cytometry to evaluate the levels of expression of P-selectin, and PAC-1 binding to platelets of 55 ITP patients and a similar number of healthy controls, treated with and without ADP. We found that platelets in ITP patients exist in an activated state. In patients who are responsive to steroids, the treatment reverses this situation. Also, the fold activation of platelets upon treatment with ADP is more in healthy controls than in ITP patients; treatment with steroids causes platelets in steroid-responsive patients to become more responsive to ADP-activation, similar to healthy controls. Thus steroids may cause changes in the ability of platelets to get activated with an agonist like ADP. Our results provide new insights into how, and why, steroid therapy helps in the treatment of ITP.Keywords
This publication has 22 references indexed in Scilit:
- In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activationBlood, 2012
- High-dose dexamethasone shifts the balance of stimulatory and inhibitory Fcγ receptors on monocytes in patients with primary immune thrombocytopeniaBlood, 2011
- Recent progress in understanding the pathogenesis of immune thrombocytopeniaCurrent Opinion in Hematology, 2010
- Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population‐based cohort studyBritish Journal of Haematology, 2010
- Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research DatabaseHaematologica, 2010
- The GPIIb/IIIa (integrin αIIbβ3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bendBlood, 2008
- Agonist‐inducible platelet activation in chronic idiopathic autoimmune thrombocytopeniaEuropean Journal of Haematology, 2007
- Flow cytometric evaluation of platelet activation in chronic autoimmune thrombocytopeniaPediatric Blood & Cancer, 2006
- The pathogenesis of immune thrombocytopaenic purpuraBritish Journal of Haematology, 2006
- Autoantibodies against platelet glycoprotein Ib/IX: a frequent finding in autoimmune thrombocytopenic purpuraBritish Journal of Haematology, 1991